# American Cancer Society Updates Prostate Cancer Screening Guideline for First Time in 16 Years

The American Cancer Society (ACS) has released an updated guideline for prostate cancer screening, marking the first revision in 16 years. The organization stated that the update aims to boost detection of the disease before it spreads. The announcement was reported by Fierce Biotech.

The revised guidance reflects a shift in the ACS’s approach to screening, though specific changes to age ranges, risk categories, or testing intervals were not detailed in the summary. The previous guideline had been in place since 2008.

**Context for the life sciences**

Prostate cancer is the second most common cancer in men worldwide. Screening typically involves the prostate-specific antigen (PSA) blood test, which has been a subject of debate over the balance between early detection and overdiagnosis. Updated guidance from a major organization like the ACS can influence clinical practice, insurance coverage, and patient awareness. For the biotech and diagnostics industries, such changes may drive demand for more precise screening tools, such as biomarker panels, liquid biopsies, or imaging-based risk stratification, that can improve detection while reducing unnecessary biopsies. The update also highlights the ongoing need for research into better screening methods and risk assessment algorithms.

Source: [original report](https://www.fiercebiotech.com/medtech/american-cancer-society-updates-prostate-cancer-screening-guidance)